Clinical trials: Chronic Pulmonary Obstruction
Pulmonary Disease, Chronic Obstructive
Comparison of Tiotropium and Ipratropium in a Double-Blind, Double-dummy, Efficacy and Safety Study in Adults With COPD
Comparison of 18 mcg of Tiotropium Inhalation Capsules and ipratropiumMetered Dose Inhaler (2 puffs of 20 mcg, four times daily) in a Double-Blind, Double-dummy, Efficacy and Safety Study in Adults with Chronic Obstructive…
- Trial name
- NCT00274040
- Testing
- Tiotropium, Ipratropium
- Where
- 18 sites in South Korea
- Volunteers
- 141 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
Study to Evaluate Efficacy/Safety of 4 Doses of CHF5259 Via Dry Powder Inhaler (DPI) in Patients With COPD
The study was designed to investigate the efficacy and safety of different doses CHF5259 a long acting muscarinic antagonist in patients with moderate to severe COPD.
- Trial name
- GlycoNEXT (NCT02680197)
- Where
- 30 sites in Czechia, Germany and 2 more
- Volunteers
- 262 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma, COPD
The Impact of PCCM on Healthcare Among Asthma or Chronic Obstructive Pulmonary Disease (COPD) or Asthma-COPD Overlap Patients
A Multi-centre, retrospective study describing the impact of PCCM standardized implementation on healthcare management among Asthma or COPD or Asthma-COPD overlap patients in Tianjin city of China, using real world electronic…
- Conditions
- Asthma, COPD, Asthma-COPD Overlap
- Trial name
- PCCM-IMPACTS (NCT04905420)
- Where
- China
- Volunteers
- 288,538 people
- Sponsor
- AstraZeneca
Post-Amputation Pain, Phantom Limb Pain
Electrical Nerve Block for Amputation Pain
The purpose of the clinical trial is to learn whether electrical nerve block via the Altius System is a safe and effective treatment for patients with post-amputation pain.
- Conditions
- Post-Amputation Pain, Phantom Limb Pain, Residual Limb Pain, Stump Pain
- Trial name
- NCT02221934
- Testing
- Altius
- Where
- 22 sites in United States
- Volunteers
- 607 people
- Sponsor
- Neuros Medical, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
Preference, Satisfaction and Ease of Use of Genuair® (Pressair™) and Breezhaler® (Neohaler™) Inhalers in Patients With COPD
Preference study: Genuair® (Pressair™) vs Breezhaler® (Neohaler™) inhalers in patients with COPD
- Trial name
- NCT01915784
- Testing
- Genuair®, Breezhaler®
- Where
- 6 sites in Germany, Spain and 1 more
- Volunteers
- 128 people
- Sponsor
- Almirall, S.A.
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The Purpose of this study is to assess the efficacy and safety of three strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT01017952
- Testing
- FF/GW642444 Inhalation Powder, GW642444 Inhalation Powder
- Where
- 183 sites in United States, Argentina and 13 more
- Volunteers
- 1,635 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Budesonide / Formoterol in Treatment of Exacerbations of COPD
The purpose of this study is to determine whether the budesonide+formoterol combination is effective in the treatment of exacerbations of COPD with a main emphasis on investigating the effects on inflammation and a secondary…
- Trial name
- NCT00239278
- Testing
- budesonide/formoterol, 2x 200/6 microgram. 4 times daily
- Where
- Netherlands
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations
Phase 3 study to evaluate the efficacy and safety of a benralizumab in patients with moderate to very severe COPD with a history of frequent COPD exacerbations and elevated peripheral blood eosinophils (≥300/μL).
- Trial name
- RESOLUTE (NCT04053634)
- Testing
- Benralizumab
- Where
- 343 sites in United States, Argentina and 28 more
- Volunteers
- 689 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Safety and Efficacy of Fluticasone Furoate (FF)/Umeclidinium(UMEC)/Vilanterol (VI) in Participants With Chronic Obstructive Pulmonary Disease (COPD)
This study will evaluate safety and efficacy of FF/UMEC/VI via ELLIPTA® inhaler. ELLIPTA is a registered trademark of GlaxoSmithKline group of companies.
- Trial name
- NCT04923347
- Testing
- FF/UMEC/VI, ELLIPTA
- Where
- 14 sites in India
- Volunteers
- 229 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
COPD is characterized by an airflow limitation, which is not fully reversible, usually progressive and accompanied by chronic cough, sputum production and dyspnea, which can be a major cause of disability and anxiety associated…
- Trial name
- NCT03034915
- Testing
- UMEC/VI 62.5/25 mcg via ELLIPTA, UMEC 62.5 mcg via ELLIPTA, Salmeterol 50 mcg via DISKUS
- Where
- 212 sites in United States, Argentina and 10 more
- Volunteers
- 2,696 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Pharmacovigilance Study to Evaluate Safety of SERETIDE in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Primary objective: Evaluation of the safety of Seretide discus administration in subjects with COPD. Treatment duration: 2 years. Study has 3 phases: Screening phase (visit 1), treatment phase (visits 2-5.
- Trial name
- NCT00662805
- Testing
- Salmeterol/Fluticasone propionate
- Volunteers
- 762 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPD
Randomized,double-blind,multicenter,multinational,parallel-group,Phase III study to demonstrate the superiority of the triple fixed combination of beclometasone + formoterol + glycopyrrolate (BDP/FF/GB) administered via…
- Trial name
- TRILOGY (NCT01917331)
- Testing
- Beclometasone/Formoterol/Glycopyrrolate, Beclometasone/Formoterol
- Where
- Hungary
- Volunteers
- 1,368 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease (COPD)
Study of Patient With Frequent COPD Exacerbations
This Study is a multicenter, non-interventional, observational, ambispective (retrospective-prospective) study to evaluate clinical and demographic characteristics, approaches to therapy in outpatients with COPD and frequent…
- Trial name
- PRIORITY-COPD (NCT07221981)
- Where
- 30 sites in Russia
- Volunteers
- 2,024 people
- Sponsor
- AstraZeneca
COPD
Indacaterol 75 μg Compared to Placebo, Assessing Time to Patient's Perception of Onset of Effect in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
This is a phase IV study of indacaterol 75 μg single-dose compared to placebo in moderate-severe COPD patients with breathing symptoms to assess time to patient's perception of onset of effect.
- Trial name
- NCT01543828
- Testing
- indacaterol
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Study to Evaluate the Safety and Dose-Range of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (MK-7123-012)
This is a two-part study conducted at multiple centers, of navarixin (SCH 527123, MK-7123) in participants with moderate to severe chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00441701
- Testing
- Navarixin 1 mg, Navarixin 10 mg, Rescue medication
- Volunteers
- 99 people
- Sponsor
- Merck Sharp & Dohme LLC
COPD
A COPD Data Registry for Participants With Frequent Exacerbations
This registry will collect data on COPD, including the course of disease, treatment patterns, and potential new therapies. The registry will also track the experience of participants and caregivers in clinical practice.
- Trial name
- AIREIC (NCT07059273)
- Sponsor
- Hoffmann-La Roche
Chronic Obstructive Pulmonary Disease
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
This is a parallel, Phase 2b/Phase 3, 3-arm study to investigate the efficacy, safety, and tolerability of subcutaneous (SC) treatment with lunsekimig compared with placebo in adult participants (aged 40 to 80 years, inclusive)…
- Trial name
- THESEUS (NCT07190222)
- Testing
- Lunsekimig
- Where
- 314 sites in United States, Argentina and 24 more
- Volunteers
- 942 people
- Sponsor
- Sanofi
Chronic Obstructive Pulmonary Disease - COPD
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
To assess the bronchodilation of three doses of formoterol fumarate (6 μg, 12 μg and 24 μg) twice daily (BID) administered via Pressair® compared to placebo and to open-label nebulized formoterol fumarate (20 μg and 40 μg).
- Trial name
- NCT02796651
- Testing
- Formoterol fumarate (6 μg), Formoterol furmarate (20 μg), Formoterol fumarate (12 μg)
- Where
- 20 sites in United States
- Volunteers
- 132 people
- Sponsor
- AstraZeneca
COPD
Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
This study evaluated the 1 year safety, tolerability and efficacy of indacaterol against placebo in the treatment of Chronic Obstructive Pulmonary Disease (COPD) patients
- Trial name
- NCT00677807
- Testing
- Indacaterol
- Where
- 190 sites in United States, Argentina and 7 more
- Volunteers
- 415 people
- Sponsor
- Novartis
COPD, Chronic Obstructive Pulmonary Disease
Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD
The dNerva Lung Denervation System is one-time treatment intended to improve breathing in Chronic Obstructive Pulmonary Disease (COPD) patients on standard medical care.
- Trial name
- AIRFLOW-4 (NCT07051707)
- Testing
- Targeted Lung Denervation (TLD)
- Where
- 10 sites in United States
- Volunteers
- 200 people
- Sponsor
- Nuvaira, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.